贝伐单抗联合多西他赛化疗方案对转移性乳腺癌患者的临床疗效

目的 探讨贝伐单抗联合多西他赛化疗方案对转移性乳腺癌患者的临床疗效.方法 入组87例患者依据随机数字表法随机分为观察组(45例)和对照组(42例).观察组采用贝伐单抗联合多西他赛化疗,对照组采用卡培他滨联合多西他赛化疗.2组均以21 d为1周期,共化疗3周期.对比分析2组总有效率、生活质量以及不良反应.结果 观察组有效率(64.45%)显著高于对照组(40.47%),差异有统计学意义(P<0.05);观察组生活质量改善率(68.89%)高于对照组(40.48%),差异有统计学意义(P<0.05);观察组胃肠道反应、骨髓抑制、手足综合征等不良反应发生率均低于对照组,差异有统计学意义(P均< 0.05);2组1 a生存率比较差异无统计学意义(P>0.05).结论 贝伐单抗联合多西他赛化疗方案对转移性乳腺癌患者临床疗效显著,可明显改善患者生活质量,降低不良反应发生率,值得进一步推广应用.

Clinical Efficacy of Bevacizumab Combined with Docetaxel Chemotherapy Regimen in the Treatment of Patients with Metastatic Breast Cancer

Objective To evaluate the clinical efficacy of bevacizumab combined with docetaxel chemotherapy regimen in the treatment of metastatic breast cancer.Methods Eighty-seven patients were randomly divided into the observation group(n=45) and the control group(n=42) according to the random number table method.Forty-five patients of the observation group was treated with bevacizumab combined with docetaxel chemotherapy,42 patients of the control group received capecitabine combined with docetaxel.The total response rate,quality of life,toxicities were compared in the two groups.Results The total response rate in the observation group(64.45%) was significantly higher than that of the control group(40.47%,P<0.05).The improving rate of quality of life in the observation group was significantly higher than that in the control group(P<0.05).The incidence of gstrointestinal reaction syndrome,bone marrow suppression,hand-feet syndrome in the observation group was significantly lower than those in the control group(P<0.05).There was no significant difference in the 1-year survival rate between the two groups(P>0.05).Conclusion Bevacizumab combined with docetaxel chemotherapy regimen is effect for patients with metastatic breast cancer,and can significantly improve the quality of life of patients,reduce the incidences of toxicities.